Medifast NYSE: MED reported first-quarter 2026 results that management characterized as an early step toward stabilizing the business as it pivots from traditional weight loss to a broader metabolic health positioning amid continued disruption from GLP-1 drug adoption.
On the company’s earnings call, Chairman and CEO Dan Chard said Medifast is “at the beginning of a period of stabilization,” pointing to the company’s “first sequential quarterly revenue growth in three years,” a second straight quarter of year-over-year coach productivity gains, improving leadership advancement, and better performance in the percentage of coaches acquiring new clients. While active earning coaches continued to decline, Chard said the company’s shift from “transformation to execution” is largely complete as it reframes weight loss as part of a metabolic health solution.
Strategy shift centers on “metabolic health” and coach-led differentiation
President Nick Johnson said the company’s “3.0 strategy” is the most significant shift since the introduction of OPTAVIA in 2017. He said Medifast has strengthened its clinical and scientific foundation, linked its science to measurable outcomes, and realigned its cost structure to reflect market realities.
Johnson framed the opportunity around metabolic health awareness and education, citing results from an online survey conducted with KRC Research. He said the survey found nearly 94% of Americans are concerned about at least one aspect of metabolic health, 85% believe metabolic dysfunction can be reversed, and 80% report limited understanding of what it means to be metabolically healthy.
At the center of Medifast’s positioning is what Johnson described as “Metabolic Synchronization,” which he said is supported by clinical outcomes tied to body composition. He highlighted results for the company’s most popular plan, including a 14% reduction in visceral fat and 98% lean mass retention over 16 weeks. Johnson also said the company’s research shows outcomes are improved when clients work with a coach, stating that clients working with a coach can see “up to 10 times greater weight loss and 17 times greater fat loss” compared with those attempting the program on their own.
In response to a question about messaging in a GLP-1 environment, Johnson said weight loss has become commoditized and that Medifast is focusing on the “quality of the weight that’s being lost,” particularly visceral fat reduction and lean mass preservation.
New metabolic system planned for rollout later in 2026
Johnson said Medifast is planning to launch a “new comprehensive metabolic system” at its next coach convention in July, featuring products with “clinically studied ingredients” aimed at advancing metabolic health. He said a pilot with a small group of clients and coaches has generated “highly encouraging” early feedback, and the company plans to roll out the new system to all clients and coaches later in the year.
The new system is structured around three phases, which Johnson described as:
Johnson said the phased approach is designed to simplify how coaches support clients through each stage of a metabolic health journey, from an initial reset to longer-term vitality and health span.
He also noted the program is eligible for HSA and FSA reimbursement on select insurance plans, which he said can make the offering more accessible.
Coach productivity rises while coach count falls
Chief Financial Officer Jim Maloney said first-quarter revenue was $76.0 million, down 34.3% from the year-ago period, primarily due to fewer active earning coaches. The company ended the quarter with approximately 14,000 active earning coaches, down 44.9% year-over-year. Maloney attributed the decline in part to “the rapid adoption of GLP-1 medications,” and also to ongoing work to build a leadership structure centered on more productive Executive Director organizations.
Despite the smaller coach base, Maloney reported average revenue per active earning coach of $5,432, up 19.2% year-over-year. He called the 19% increase the largest quarterly gain in five years, with a 16% sequential increase he said was the highest in eight years. Johnson said the productivity improvement was not driven by larger average order sizes, which he said have remained consistent, but instead by “an increasing number of clients per coach” and “their length of stay.”
Johnson also pointed to improving field engagement, including increased cadence of coach-led meetings, a well-attended coach incentive trip and Go Global event, and momentum in referrals. He said March ended with a “record high percentage of new clients coming from referrals,” and that coaches participating in the referral program are achieving “two times higher client acquisition rates” than non-participants.
Margins pressured by volume; cost actions and Q4 profitability improvement targeted
Maloney said gross profit decreased 38.6% year-over-year to $51.8 million, and gross margin fell to 68.1% from 72.8%, primarily due to lower leverage on fixed costs. SG&A expense declined 35.6% to $55.1 million, driven by lower coach compensation, reduced company-led marketing, a one-time $2.2 million gain from the sale of a Maryland distribution center, and lower employee compensation tied to a workforce realignment.
Loss from operations was $3.3 million, and net loss was $2.1 million, or $0.19 per share, compared with a net loss of $0.8 million, or $0.07 per diluted share, in the prior-year quarter.
Maloney said Medifast ended the quarter with $168.9 million in cash, cash equivalents, and investments and no debt. Chard said the balance sheet remains strong with “substantial cash and investments of approximately $169 million.”
Looking ahead, Maloney said Medifast expects second-quarter revenue of $60 million to $80 million and a loss per share of $0.50 to $1.00. For full-year 2026, the company reiterated its guidance for revenue of $270 million to $300 million and a loss per share of $1.55 to $2.75. Management said it expects improvements toward returning to profitability to begin in the fourth quarter of 2026 following the launch of the new product line, with further improvements targeted into 2027.
Leadership transition: Chard to step down as CEO June 1
In closing remarks, Chard reiterated that he plans to step down as chief executive officer effective June 1. He said he will continue to serve as chairman of the board following the transition and expressed confidence in Johnson’s ability to lead the company, noting that Johnson has been “instrumental in shaping and executing the strategy” discussed on the call.
About Medifast NYSE: MED
Medifast, Inc NYSE: MED is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client's weight‐loss journey.
Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight‐management solutions.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Medifast, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medifast wasn't on the list.
While Medifast currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
